Eli Lilly (LLY)

Eli Lilly cut its 2025 profit outlook after strong Q1 sales from Mounjaro and Zepbound and a $1.57 billion charge tied to a cancer drug acquisition.

The company cut its adjusted earnings per share guidance for the full year to $22.50 to $24.00, down from its previous forecast of $20.78 to $22.28.

The drugmaker cut its profit guidance for the year, but kept its sales outlook.

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 45.2% year on year to $12.73 billion. The company expects the full year’s revenue to be around $59.5 billion, close to analysts’ estimates. Its non-GAAP profit of $3.34 per share was 3.4% below analysts’ consensus estimates.

Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year?

U.S. stock futures rose early Thursday morning, following the robust earnings of two "Mag 7" companies after markets closed on Wednesday.

Needham called the tie-up a “groundbreaking partnership” and said it alleviates investor concerns around Hims’ ability to hit its 2025 weight loss revenue guidance.

Notwithstanding the recent seven-session run, the S&P 500 Index ended April — a historically strong month — with a loss of 0.8%.

Eli Lilly, a pharmaceutical leader in obesity and diabetes treatment, is back in the spotlight, and for good reason.

Eli Lilly reports 1Q earnings on Thursday, with EPS of $3.05 and revenues of $12.67 billion expected. Stock is up 14.35% in past year.

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow before market hours. Here’s what to look for.

Eligible self-pay patients without insurance can now access prescriptions for Zepbound in single-dose vial form through the WeightWatchers app.

Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 132% in the afternoon session after the company announced plans to make it easier for its members to access Eli Lilly's FDA-approved weight loss drug Zepbound. Given the success of weight loss drugs with regulatory approval and the crackdown on knock-offs, expanding the distribution of Zepbound should accelerate adoption. Additionally, companies such as WeightWatchers should benefit from increased sales volume and greater customer loyalty as they align themselves with medically endorsed treatments.

Eli Lilly (LLY) will report Q1 results on Thursday. Analysts expect in line results with focus on tirizepatide and obesity franchise.

Cantor Fitzgerald thinks the GLP-1 diet drug VK2735 will be a "multi-blockbuster" for Viking stock.

Hims & Hers partners with Novo Nordisk to offer Wegovy access online with clinical support, expanding its weight loss care and revenue strategy.